Basal Cell Nevus Syndrome, Gorlin Syndrome
Conditions
Brief summary
The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.
Detailed description
This is a Phase II, 18 month, double blind, randomized placebo-controlled, two arm multicenter clinical study design. During the 18-month treatment period, the safety and chemopreventive efficacy of 150 mg/day GDC-0449 versus placebo will be assessed, and include evaluations of the skin at monthly intervals for the first three months and then every 3 months for the next 15 months. Removal of new surgically eligible BCCs (SEBs) will be done by primary skin care physicians (PSCPs) or at Study Centers. A Data Safety Monitoring Board (DSMB) will review unblinded results for an interim analysis when 20 subjects have completed 12 months of drug. This review will focus on adverse events and efficacy results. Subjects will be monitored for the development of new SEBs after they discontinue study treatment. At the end of the 18 months, given that the observed adverse events are minimal, patients on placebo will be offered the opportunity to take GDC-0449 for 18 months in an open label continuation, followed by six months observation, and patients on GDC449 will be monitored for the next 24 months for assessment of the duration of benefit after stopping the drug.
Interventions
DRUGGDC-0449
capsule, 150 mg, one pill daily, 18 months
Sponsors
Genentech, Inc.
UCSF Benioff Children's Hospital Oakland
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
The subject: * has had diagnosed at least 10 SEB (of diameter 3 mm diameter or greater on the nose or periorbital skin, 5 mm or greater elsewhere on the face, or 9 mm or greater on non-facial areas excluding the skin below the knees) during the two years before study entry, as documented histologically in physicians' records and/or diagnosed clinically by a Study Investigator at baseline. * meet diagnostic criteria for basal cell nevus syndrome * is willing to abstain from application of non-study topical medications to the skin for the duration of the study, including prescription and over the counter preparations. Subjects will be encouraged to use sunscreen (SPF 15) at least once daily on all exposed skin sites. * is willing to forego treatment of BCCs unless the BCCs are documented by Study Investigators, preferably on two separate visits, except when the PSCP believes that delay in treatment potentially might compromise the health of the subject. * has normal laboratory tests as defined by the following: Normal hematopoietic capacity, Normal hepatic function: AST and ALT greater than or equal to 2x the upper limit of normal (ULN) Total bilirubin within normal range 0.20 mg/dl to 1.50 mg/dl or within 3x ULN for patients with Gilbert's disease Normal renal function: normal serum creatinine or measured creatinine clearance less than 50 mL/minute. Fasting cholesterol greater than or equal to 220 untreated * be willing to not donate blood or semen for three months following discontinuation of Study medications. * is willing to avoid pregnancy in his partner as defined by the following: Male subject is willing to use a latex condom during the study and for 3 months after the last dose during sexual contact with a female of childbearing potential, even if he has had a successful vasectomy. His partner must also use a form of birth control
Exclusion criteria
The subject: * has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study. Specifically these include the use of: (i) glucocorticoids to more than 5% of the skin (ii) retinoids systemically or topically to more than 5% of the skin during the six months prior to study entry; (iii) alpha-hydroxy acids to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod systemically or topically to the skin above the knees during the six months prior to study entry. (v) treatment with systemic chemotherapy within one year prior to starting study medication. * has a history of hypersensitivity to any of the ingredients in the study medication formulations. * is unable to return for follow-up visits and tests. * has uncontrolled systemic disease, including known HIV positive patients. * has history of congestive heart failure. * has uncontrolled hypocalcemia, hypomagnesemia, or hypokalemia * has clinically important history of liver disease, including viral or hepatitis, current alcohol abuse, or cirrhosis. * has any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study. * has a history of invasive cancer within the past five years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or CLL Stage 0. * has current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study while enrolled in this study. * is a female who is pregnant, plans to ever to become pregnant, capable of becoming pregnant or is breast feeding. * is a male who is unwilling or unable to comply with pregnancy prevention measures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of New Surgically Eligible Basal-cell Carcinomas | 3 months of receiving study drug | Number of new surgically eligible basal-cell carcinomas per patient per year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period | Baseline and 18 months | — |
| Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment | These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported. | The number of new surgically eligible basal-cell carcinomas per patient per month is reported. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Sugar Pill placebo pill by mouth once daily
GDC-0449: capsule, 150 mg, one pill daily, 18 months | 15 |
| GDC-0449 vismodegib 150MG by mouth once daily
GDC-0449: capsule, 150 mg, one pill daily, 18 months | 26 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Reallocated to or Continued Vismodegib | Adverse Event | 2 | 1 |
| Reallocated to or Continued Vismodegib | Death | 1 | 1 |
| Study Start | Adverse Event | 0 | 3 |
| Study Start | Disease Progression | 1 | 0 |
Baseline characteristics
| Characteristic | Sugar Pill | GDC-0449 | Total |
|---|---|---|---|
| Age, Continuous | 53 years STANDARD_DEVIATION 8 | 54 years STANDARD_DEVIATION 8 | 54 years STANDARD_DEVIATION 8 |
| Region of Enrollment United States | 15 participants | 26 participants | 41 participants |
| Sex: Female, Male Female | 6 Participants | 8 Participants | 14 Participants |
| Sex: Female, Male Male | 9 Participants | 18 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 15 | 2 / 40 |
| other Total, other adverse events | 12 / 15 | 40 / 40 |
| serious Total, serious adverse events | 2 / 15 | 21 / 40 |
Outcome results
Primary
Number of New Surgically Eligible Basal-cell Carcinomas
Number of new surgically eligible basal-cell carcinomas per patient per year
Time frame: 3 months of receiving study drug
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Number of New Surgically Eligible Basal-cell Carcinomas | 34 events per patient year | Standard Deviation 1.32 |
| GDC-0449 | Number of New Surgically Eligible Basal-cell Carcinomas | 2 events per patient year | Standard Deviation 0.12 |
Secondary
Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period
Time frame: Baseline and 18 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sugar Pill | Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period | 55 Millimeters |
| GDC-0449 | Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period | -60 Millimeters |
Secondary
Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment
The number of new surgically eligible basal-cell carcinomas per patient per month is reported.
Time frame: These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported.
Population: The incidence of new surgically eligible basal-cell carcinomas after stopping vismodegib was analysed in an exploratory analysis of the patients who crossed over to vismodegib and were followed up for at least 6 months after stopping vismodegib (n=5).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Sugar Pill | Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment | 1.7 carcinomas per patient per month | Standard Deviation 1.5 |
| GDC-0449 | Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment | 0.06 carcinomas per patient per month | Standard Deviation 0.12 |